T0	Participants 40 223	coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection:
T1	Participants 372 399	(EVG/COBI/FTC/TDF, n = 348)
T2	Participants 457 479	(EFV/FTC/TDF, n = 352)